Michael Mulkerrin

Michael Mulkerrin

Chief Tech/Sci/R&D Officer at ADC THERAPEUTICS SA

Net worth: 397 531 $ as of 31/03/2024

69 year
Health Technology
Consumer Services

Profile

Michael Mulkerrin is currently the Chairman-Biologics & Biotechnology Expert at The United States Pharmacopeia and the Chief Technical Operations Officer at ADC Therapeutics SA. He previously worked as a Senior Director-Process Sciences at Amgen, Inc., Interim Director at Abgenix, Inc., Principal at Genentech, Inc., Vice President-Process Development & Manufacturing at OncoMed Pharmaceuticals, Inc., and Head-Chemistry Manufacturing & Control Division at ADC Therapeutics SA. Mulkerrin holds a doctorate from the University of Georgia and an undergraduate degree from the University of Massachusetts.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
01/02/2023 88,537 ( 0.11% ) 397 531 $ 31/03/2024

Michael Mulkerrin active positions

CompaniesPositionStart
ADC THERAPEUTICS SA Chief Tech/Sci/R&D Officer 01/11/2022
Corporate Officer/Principal 01/01/2010
All active positions of Michael Mulkerrin

Former positions of Michael Mulkerrin

CompaniesPositionEnd
ADC THERAPEUTICS SA Corporate Officer/Principal -
AMGEN INC. Corporate Officer/Principal -
Corporate Officer/Principal -
Director/Board Member -
ONCOMED PHARMACEUTICALS INC Corporate Officer/Principal -
See the detail of Michael Mulkerrin's experience

Training of Michael Mulkerrin

University of Georgia Doctorate Degree
University of Massachusetts Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michael Mulkerrin's experience

Connections

83

1st degree connections

8

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies2
AMGEN INC.

Health Technology

ADC THERAPEUTICS SA

Health Technology

Private companies4

Health Technology

Health Technology

Health Technology

Health Technology

See company connections
  1. Stock Market
  2. Insiders
  3. Michael Mulkerrin